Article Dans Une Revue British Journal of Clinical Pharmacology Année : 2025

Contribution of Addictovigilance data to assess adverse‐events linked to psychoactive substances in children and adolescents

1 UM - Université de Montpellier
2 PCCEI - Pathogenesis and Control of Chronic and Emerging Infections
3 CHU Montpellier = Montpellier University Hospital
4 INSERM - Institut National de la Santé et de la Recherche Médicale
5 Département de Pharmacologie Médicale et de Toxicologie [CHRU Montpellier]
6 CSAPA - Centre de Soins, d’Accompagnement et de Prévention en Addictologie Pierre Nicole [Paris]
7 CEIP-A Paris - Centre d’Evaluation et d’Information sur la Pharmacodépendance (CEIP-A) et d’Addictovigilance de Paris
8 CEIP-A Grenoble - Centre d’évaluation et d’information sur la pharmacodépendance – addictovigilance de Grenoble
9 Centre de Soins, d’Accompagnement et de Prévention en Addictologie - CSAPA - CHU Grenoble Alpes
10 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
11 Département Hospitalo-Universitaire de Pharmacologie de Bordeaux
12 Université de Clermont-Ferrand
13 Service Pharmacologie Médicale [CHU Clermont-Ferrand]
14 Université de Lille
15 Pôle Recherche - Département de Pharmacologie Médicale [Lille]
16 CEIP - Service Hospitalo-Universitaire de Pharmaco-Toxicologie [Bron]
17 Hôpitaux Sud - Hôpital Sainte-Marguerite [CHU - APHM]
18 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
19 CEIP-A - Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance [CHU de Nantes]
20 LNEC [Poitiers] - Laboratoire de neurosciences expérimentales et cliniques [U 1084]
21 UFR Santé [Poitiers] - Université de Poitiers – UFR Santé [Faculté de Médecine et de Pharmacie]
22 Service de pharmacologie clinique et vigilances [CHU de Poitiers]
23 Equipe EQUITY (CERPOP)
24 Service Pharmacologie Clinique [CHU Toulouse]
25 CESP - Centre de recherche en épidémiologie et santé des populations

Résumé

Aims: We sought to characterize adverse events and deaths associated with the use of psychoactive substances in children and adolescents.
Methods: Two French Addictovigilance databases were analysed: spontaneous reports and deaths over the period 2016–2021, in subjects aged 10–<18 years. An unsupervised classification was implemented on consumption data (medications or nondrug substances [NDS]) to identify subject clusters.
Results: A total of 1544 spontaneous reports were analysed, comprising mainly boys (65.6%), aged on average 16 ± 1 years. Four clusters were identified: The cannabinoids users cluster (n = 597) was typified by the use of cannabis or/and synthetic cannabinoids (95.1%), with psychiatric (67.7%) and digestive disorders (16.7%). The medications/solvents/cannabidiol users cluster (n = 699) was distinguished by the use of medications or NDS including nitrous oxide/cannabidiol, with mainly neurological disorders (46.5%). The polydrug users cluster (n = 177) includes polyusers (98.3%) of NDS and medications. These users mainly have substance use disorders (63.8%). The psychotropic medications users cluster (n = 71) was characterized by the use of psychotropic medications. This cluster appeared to be correlated with psychiatric and organic disorders. The death database recorded 44 deaths, mainly in boys (61.4%) aged over 15 years. The main substances involved in the deaths were NDS (70.5%) and methadone. In 68.2% of cases, a single substance was responsible for the death.
Conclusion: The adverse events related to the abuse of psychoactive substances identified in children and adolescents and the emerging signals show the need for increased surveillance and the implementation of prevention campaigns adapted to each group of consumers.

Fichier principal
Vignette du fichier
Br J Clin Pharmacol - 2025 - Peyrière - Contribution of Addictovigilance data to assess adverse‐events linked to.pdf (1.28 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-05295482 , version 1 (03-10-2025)

Licence

Identifiants

Citer

Hélène Peyrière, Anne Batisse, Nathalie Fouilhé Sam-Laï, Amélie Daveluy, Christine Fournier-Choma, et al.. Contribution of Addictovigilance data to assess adverse‐events linked to psychoactive substances in children and adolescents. British Journal of Clinical Pharmacology, 2025, 91 (10), pp.2957-2968. ⟨10.1002/bcp.70133⟩. ⟨hal-05295482⟩
247 Consultations
124 Téléchargements

Altmetric

Partager

  • More